The Number One Chosen Dermal Filler Collection
Celebrates with Exclusive Offers
IRVINE,
Calif., Aug. 1, 2023 /PRNewswire/ -- Allergan
Aesthetics, an AbbVie company (NYSE: ABBV), announces the first
ever JUVÉDERM® Day on Wednesday, August 16, 2023. The celebration
recognizes the aesthetics providers and patients who have made the
JUVÉDERM® Collection of Fillers the number one
chosen* collection of dermal fillers in the U.S.1
JUVÉDERM® Day provides both new and loyal consumers
savings and exclusive offers through Allē, the Allergan Aesthetics
loyalty program.
"To celebrate the first ever JUVÉDERM® Day, we wanted
to do something special, which is why we're offering consumers this
first-of-its-kind promotion," said Jasson
W. Gilmore, Senior Vice President, Allergan Data Labs at
Allergan Aesthetics. "JUVÉDERM® Day provides an
opportunity to encourage consumers to take advantage of special
offers and book a consultation with an aesthetic specialist. It is
also a chance to celebrate the accomplishments of a brand that has
revolutionized the dermal filler category with scientifically
proven products and positive results."
Consumers interested in participating in JUVÉDERM®
Day are encouraged to join Allē to take advantage of exciting
offers. These offers include:
- BOGO Gift Cards: On Wednesday, August 16, 2023, starting at
9 a.m. Pacific Time and while
supplies last, Allē Members who purchase a $75 JUVÉDERM® gift card at
JuvedermDay.com will receive another $75 JUVÉDERM® gift card for free.
- Triple Take: In addition to the BOGO gift card
offer, Allē Members who book a consultation between August 16 and August 31, 2023, and
receive treatment with three syringes from the JUVÉDERM®
Collection of Fillers during the same visit will receive triple the
Allē points. Consumers can combine their points and gift card
savings to save up to $255 in total
value towards treatments with the Allergan Aesthetics portfolio of
products.
The exclusive BOGO gift card and Triple Take offers are
available to both new and existing Allē Members. Terms and
Conditions apply. To join Allē, visit alle.com.
"I am thrilled to celebrate the first ever JUVÉDERM®
Day with my patients! I have trusted and utilized the
JUVÉDERM® Collection of Fillers for more than a decade,"
said Dr. Anna Guanche,
Board-Certified Dermatologist. "The breadth of JUVÉDERM®
products in the collection enables me to provide each patient with
a customized approach based on their unique needs and
anatomy.2-7 JUVÉDERM® Day gives patients who
are interested in trying JUVÉDERM® for the first time a
great opportunity to speak with their aesthetic specialist to
determine which product in the JUVÉDERM® Collection of
Fillers may be right for them."
The JUVÉDERM® Collection of Fillers currently
offers six specially formulated, modified hyaluronic acid (HA)
fillers to address patients' varying facial treatment needs:
JUVÉDERM® VOLUMA® XC,
JUVÉDERM® VOLBELLA® XC,
JUVÉDERM® VOLLURE® XC,
JUVÉDERM® Ultra Plus XC,
JUVÉDERM® Ultra XC,
JUVÉDERM® VOLUX® XC.2-7 The
safety and efficacy of the JUVÉDERM® Collection of
Fillers has been demonstrated in more than 330 clinical
studies.8 Patients who are interested in HA fillers
should schedule a consultation with their aesthetic specialist to
see if they're a candidate and discuss a treatment plan customized
to their desired outcome.
Consumers and new patients who receive aesthetic treatment from
the Allergan Aesthetics portfolio of products can also enroll in
Allē, the Allergan Aesthetics loyalty rewards program, to unlock
access to curated content, exclusive offers, and personalized
rewards that can be used for savings on the Allergan Aesthetics
portfolio of products and redeemed at a participating provider's
office, subject to applicable program terms and conditions. Allē is
the first and only loyalty program in the aesthetics market to also
offer consumers the ability to earn points on over 40 non-Allergan
Aesthetics treatments and brands.
Recognized by National Day Archives as an official holiday on
the National Day Registry™, JUVÉDERM® Day will be held
annually on the third Wednesday of August.
For more information on the JUVÉDERM® Collection
of Fillers, visit Juvederm.com and follow @JUVÉDERM on Instagram
and TikTok.
About Allergan Aesthetics
At Allergan Aesthetics, an
AbbVie company, we develop, manufacture, and market a portfolio of
leading aesthetics brands and products. Our aesthetics portfolio
includes facial injectables, body contouring, plastics, skin care,
and more. Our goal is to consistently provide our customers with
innovation, education, exceptional service, and a commitment to
excellence, all with a personal touch. For more information,
visit AllerganAesthetics.com.
About AbbVie
AbbVie's mission is to discover and
deliver innovative medicines and solutions that solve serious
health issues today and address the medical challenges of tomorrow.
We strive to have a remarkable impact on people's lives across
several key therapeutic areas – immunology, oncology, neuroscience,
and eye care – and products and services in our Allergan Aesthetics
portfolio. For more information about AbbVie, please visit us at
www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram,
YouTube and LinkedIn.
JUVÉDERM® Injectable Gel Fillers Important
Information
APPROVED USES
JUVÉDERM® VOLUX® XC injectable
gel is for deep injection to improve moderate to severe loss of
jawline definition in adults over the age of 21.
JUVÉDERM® VOLUMA® XC injectable gel is for
deep injection in the cheek area to correct age-related volume loss
and for augmentation of the chin region to improve the chin profile
in adults over 21.
JUVÉDERM® VOLLURE® XC,
JUVÉDERM® Ultra Plus XC, and JUVÉDERM® Ultra
XC injectable gels are for injection into the facial tissue for the
correction of moderate to severe facial wrinkles and folds, such as
nasolabial folds. JUVÉDERM® VOLLURE® XC
injectable gel is for adults over 21.
JUVÉDERM® Ultra XC injectable gel is also for
injection into the lips and perioral area for lip augmentation in
adults over 21.
JUVÉDERM® VOLBELLA® XC injectable gel is
for injection into the lips for lip augmentation and correction of
perioral lines, and for injection into the undereye hollows to
improve the appearance of undereye hollows in adults over the age
of 21.
IMPORTANT SAFETY INFORMATION
Are there any reasons why I should not receive any
JUVÉDERM® formulation?
Do not use these
products if you have a history of multiple severe allergies or
severe allergic reactions (anaphylaxis), if you are allergic to
lidocaine or the Gram-positive bacterial proteins used in these
products, or if you have had previous allergic reactions to
hyaluronic acid fillers.
What warnings should my doctor advise me about?
- One of the risks with using dermal fillers is the unintentional
injection into a blood vessel. The chances of this happening are
very small, but if it does happen, the complications can be serious
and may be permanent. These complications, which have been reported
for facial injections, can include vision abnormalities, blindness,
stroke, temporary scabs, or permanent scarring of the skin. Most of
these events are irreversible.
- If you have changes in your vision, signs of a stroke
(including sudden difficulty speaking, numbness or weakness in your
face, arms or legs, difficulty walking, face drooping, severe
headache, dizziness, or confusion), white appearance of the skin,
or unusual pain during or shortly after treatment, you should
notify your health care practitioner immediately.
- The use of dermal fillers where skin sores, pimples, rashes,
hives, cysts, or infections are present should be postponed, as
this may delay healing or make skin problems worse.
- The effectiveness of removal of any dermal filler has not been
studied.
What precautions should my doctor advise me about?
- JUVÉDERM® VOLBELLA® XC should only be
injected into undereye hollows by doctors who have completed the
necessary training for this treatment area. To find a doctor, visit
Juvederm.com/find-a-specialist. Doctors who complete the training
will be listed with a symbol
- The safety of these products for use during pregnancy or
while breastfeeding has not been studied
- The safety of JUVÉDERM® VOLUMA® XC
has not been studied in patients under 35 years or over 65 years
for cheek augmentation, or under 22 years and over 80 years for
chin augmentation. The safety of JUVÉDERM®
VOLUX® XC, JUVÉDERM®
VOLLURE® XC and JUVÉDERM®
VOLBELLA® XC has not been studied in patients under
22 years, and the safety of JUVÉDERM® Ultra Plus XC and
JUVÉDERM® Ultra XC has not been studied in patients
under 18 years
- The safety and effectiveness of treatment
with JUVÉDERM® products in anatomical regions
outside of their approved uses have not been established in
clinical studies
- If you have a history of excessive scarring (thick, hard scars)
or pigmentation disorders, treatment in these patients has not been
studied and may result in additional scars or changes in
pigmentation
- If you are planning other procedures including laser treatments
or a chemical peel, there is a possible risk of inflammation at the
treatment site if these procedures are performed closely before or
after JUVÉDERM® injectable gel treatment
- Tell your doctor if you are on therapy used to reduce your
body's natural defense system (such as steroids, chemotherapy, and
medicines to treat autoimmune diseases, HIV, and AIDs), as
these may increase your risk of infection; and medications that can
prolong bleeding (such as aspirin, ibuprofen, or other blood
thinners), as these may result in increased bruising or bleeding at
the injection site.
- Avoid applying makeup for 12 hours after treatment and minimize
strenuous exercise, exposure to extensive sun or heat, and
alcoholic beverages within the first 24 hours following treatment,
as these may cause temporary redness, swelling, and/or itching at
the injection site
- JUVÉDERM® VOLUMA® XC was not studied in
patients with significant loose skin of the chin, neck, or jaw
- The effect of JUVÉDERM® VOLUMA® XC
injection into the chin on facial hair growth has not been
studied
- Patients who experience skin injury near the site
of JUVÉDERM® VOLUMA® XC injection may be
at a higher risk for adverse events
- Tell your doctor if you have already been injected with dermal
fillers in the same area as the one(s) you are about to be treated
for. This information helps your doctor decide when and whether you
should get treatment
What are possible side effects of treatment?
The most
commonly reported side effects with JUVÉDERM® injectable
gels were redness, swelling, pain, tenderness, firmness,
lumps/bumps, bruising, discoloration, and itching. For
JUVÉDERM® VOLBELLA® XC, dryness was also
reported.
These side effects are consistent with other facial injection
procedures and most will resolve within 30 days. Your doctor may
choose to treat side effects persisting longer with antibiotics,
steroids, or hyaluronidase (an enzyme that breaks down hyaluronic
acid).
As with all skin injection procedures, there is a risk of
infection.
To report a side effect with any product in the
JUVÉDERM® Collection, please call the
Allergan® Product Support Department at
1‑877‑345‑5372. Please also visit Juvederm.com or talk to
your doctor for more information.
Products in the JUVÉDERM® Collection are available
only by a licensed physician or properly licensed practitioner.
* Based on a March 2023 Provider
Survey Data (N=953)1
References:
- Data on File, Allergan; Dermal Filler AMT, March 2023.
- JUVÉDERM® VOLUMA® XC Patient Labeling,
2020.
- JUVÉDERM® VOLBELLA® XC Patient Labeling,
2021.
- JUVÉDERM® Ultra XC Patient Labeling, 2020.
- JUVÉDERM® Ultra Plus XC Patient Labelling,
2020.
- JUVÉDERM® VOLLURE® XC Patient
Labelling, 2020.
- JUVÉDERM® VOLUX® XC Patient Labeling,
2022.
- Data on file, Allergan; Number of Allergan product
publications, July 20,
2022.
© 2023 AbbVie. All rights reserved. JUVÉDERM and its designs are
trademarks of Allergan Holdings France SAS, and AbbVie company, or
its affiliates. All other trademarks are property of their
respective owners.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/allergan-aesthetics-announces-first-ever-juvederm-day-301889889.html
SOURCE AbbVie